Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; none of the 24 sources its claims cite is checked for support yet.

Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy

Open access
Perri, Paolo, Curcio, Federica, De Luca, Michele, Piro, Paolo, Trombino, Sonia, Cassano, Roberta · 2025 · Pharmaceuticals

Abstract

Background/Objectives: The safe completion of a non-invasive procedure is crucial to the success of an endovascular approach. Chitosan, a natural polysaccharide derived from chitin, is an ideal material for the study and application of medical devices in post-operative wound management. Methods: The present work is based on a retrospective study conducted on a sample of patients treated with Axiostat (a sterile, single-use, non-absorbable dressing), composed of 100% chitosan and designed to instantly stop bleeding through a mucus adhesion mechanism for the treatment of conditions such as Leriche’s syndrome. The objective was to evaluate the efficacy and safety of the hemostatic Axiostat dressing in patients undergoing anticoagulant and/or antiplatelet therapy in whom endovascular procedures using the axillary artery as an access site are performed to treat Leriche syndrome. Results: The obtained results showed that Axiostat is safe and effective in promoting hemostasis at the axillary vascular access site even when prolonged hemostasis was required in patients on antiplatelet and anticoagulant therapy. The mean time to hemostasis was 5.75 min in all types of patients considered.

Overview

CoChat Summary

TL;DR

In a single-center retrospective study of 60 patients with Leriche syndrome undergoing endovascular procedures via left axillary access, adjunctive Axiostat chitosan dressing with manual compression achieved a mean time to hemostasis of 5.75 min despite anticoagulant/antiplatelet therapy. The authors conclude Axiostat is safe and effective, while calling for multicenter randomized trials.

Key findings

  • Among 60 patients (mean age 67.4 years), primary success was 100% in single- and dual-antiplatelet therapy and 95–98% in anticoagulant and/or combined anticoagulant therapy; mean time to hemostasis was 5.75 min, with median approximately 5 min.
  • At the end of the 10 min observation period, hemostatic success was 99.5% (later stated as 100% in Table 5); healing at 7- and 30-day follow-up occurred in 99.9% of cases.
  • Access-site complication rate was 1.8%, including one hematoma in patients on anticoagulant therapy and two in patients on anticoagulant and/or combination antiplatelet therapy; five pseudoaneurysms occurred in dual antiplatelet therapy and two in anticoagulant therapy; 1.2% required surgical intervention, with no dissection or arteriovenous fistula.
  • Mean INR before and after treatment was 1.3 (±0.2); PCA using the first two principal components captured approximately 73% of total variance, with higher BMI, diabetes, and hyperlipidemia associated with prolonged hemostasis times.

Methods

  • Monocentric retrospective analysis at Annunziata Hospital, Cosenza, Italy, from September 2022 to February 2024, including 60 consecutive patients who underwent endovascular treatment for Leriche syndrome with left axillary artery access and Axiostat-assisted manual compression; inclusion and exclusion criteria were specified.
  • Procedure included local lidocaine anesthesia, CT and ultrasound assessment, percutaneous access via Seldinger technique, heparin 5000 I.U., kissing stent placement (Begraft 8 × 57 mm), then three-finger manual compression with Axiostat for 10 min for 4–8 Fr sheaths, followed by a secondary adhesive compression dressing for 12 h and ultrasound follow-up.
  • Statistical analysis used one-way ANOVA and Brown–Forsythe tests with p < 0.05 and p < 0.001 thresholds in MATLAB R2023a; PCA was performed with normalization and centering using The Unscrambler X 10.4.

Limitations

  • Paper-stated: retrospective single-center observational design, lack of randomization, and absence of a control group; the authors note the need to extend the study to other vascular surgery departments and larger populations, to include CT at last follow-up, to use standardized cross-checked data collection forms, and to conduct multicenter randomized clinical trials.
  • Evident from the text: the sample is small (n = 60) and single-center, limiting generalizability; some reported outcome numbers are internally inconsistent (e.g., a 1.8% complication rate alongside one and two hematoma cases, and 99.5% versus 100% 10-min hemostatic success), which may affect reliability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ph18040584

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Chitosan structure.
Figure 1 Chitosan structure.CC BY · PubMed Central
Scheme 1 Axiostat application on axillar access in Leriche syndrome treatment.
Scheme 1 Axiostat application on axillar access in Leriche syndrome treatment.CC BY · PubMed Central
Figure 2 Graphical representation of the distribution of complications.
Figure 2 Graphical representation of the distribution of complications.CC BY · PubMed Central
Figure 3 Graphical representation to evaluate the hemostasis time achievement of different groups of patients.
Figure 3 Graphical representation to evaluate the hemostasis time achievement of different groups of patients.CC BY · PubMed Central
Figure 4 Scores and loading plots calculated in chemometric analysis, PC1 vs. PC2. ** activated partial thromboplastin time.
Figure 4 Scores and loading plots calculated in chemometric analysis, PC1 vs. PC2. ** activated partial thromboplastin time.CC BY · PubMed Central
Figure 5 Introduction of the sheath 8 Fr for the endovascular procedure.
Figure 5 Introduction of the sheath 8 Fr for the endovascular procedure.CC BY · PubMed Central
Figure 6 Axiostat application on the axillar arterial access site.
Figure 6 Axiostat application on the axillar arterial access site.CC BY · PubMed Central
Figure 7 Hemostasis assessment after Axiostat removal.
Figure 7 Hemostasis assessment after Axiostat removal.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 15 Not checked · 43 Own results and interpretations

17 more claims

Create a free account to see all 58 claims and to verify the 24 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 27 references

Research works printed but not linked: 2

  1. Kholmurodov, 2023, Leriche’s Syndrome, Gold. Brain, 1, 104
  2. Archer, 2023, The seldinger technique: A revolution in medicine, ANZ J. Surg., 93, 184

Cited by

See all 6

Metadata

Authors
Perri, P., Curcio, F., De Luca, M., Piro, P., Trombino, S., & Cassano, R.
Affiliations
  • Ospedale Annunziata di Cosenza (IT)
  • University of Calabria (IT)
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Arcavacata, 87036 Rende, Italy
Corresponding author
  • Trombino, Sonia
  • Cassano, Roberta
Venue
Pharmaceuticals
Publisher
MDPI AG
Published
2025-04-16
Volume
18
Issue
4
Pages
584
ISSN
1424-8247 (ISSN-L)
OpenAlex
W4409503510
Cited by
6
References
27
Citations by year
2026: 5 · 2025: 1
FWCI
3.11
Type
journal article
Language
en
Open access
Locations
  • Pharmaceuticals (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archive of Doctoral Theses and Digital Collections (University of Calabria) (submittedVersion)
Funders
  • Department of Pharmacy and Health and Nutrition Sciences Department of Excellence L. (232/2016, 2014-2020—ARS01_00568—SI.F.I.PA.CRO.DE., PA.CRO.DE.)
  • PON R&amp;I (232/2016, 2014-2020—ARS01_00568—SI.F.I.PA.CRO.DE., PA.CRO.DE.)
  • Development and Industrialization of Innovative Drugs for Personalized Molecular Therapy (232/2016, 2014-2020—ARS01_00568—SI.F.I.PA.CRO.DE., PA.CRO.DE.)
Topics
  • Health Sciences › Medicine › Hematology › Hemostasis and retained surgical items
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vascular Procedures and Complications
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Central Venous Catheters and Hemodialysis
Keywords
chitosan, hemostatic dressings, Leriche syndrome, anticoagulation, antiplatelet therapy, endovascular intervention, axillary artery access, mucus adhesion, wound care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-17, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-17 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy. https://app.cochat.ai/papers/10.3390/ph18040584
The paper
Perri, P., Curcio, F., De Luca, M., Piro, P., Trombino, S., & Cassano, R. (2025). Evaluation of Chitosan-Based Axiostat as Hemostatic Dressing for Endovascular Procedures in Patients with Leriche Syndrome on Anticoagulant Therapy. Pharmaceuticals. https://doi.org/10.3390/ph18040584

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.